Rare disease

Atypical tumour-like involvement of the colon in Henoch-Schönlein purpura successfully treated with the administration of factor XIII

Katuyoshi Ando,¹ Mikihiro Fujiya,¹ Ryuji Sugiyama,¹ Toshie Nata,¹ Yoshiki Nomura,¹ Nobuhiro Ueno,¹ Shin Kashima,¹ Chisato Ishikawa,¹ Yuhei Inaba,¹ Takahiro Ito,¹ Kentaro Moriichi,¹ Kotaro Okamoto,¹ Katsuya Ikuta,¹ Jiro Watari,² Yusuke Mizukami,¹ Yutaka Kohgo¹

¹Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan;

²Division of Upper Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan

Correspondence to Dr Mikihiro Fujiya, fjym@asahikawa-med.ac.jp

Summary

Henoch-Schönlein purpura (HSP) is a type of systemic vasculitis of the small vessels, which frequently involves the skin, kidney and gastrointestinal tract. While the typical intestinal features of HSP include diffuse mucosal redness, small ring-like petechiae and haemorrhagic erosions, tumour-like lesions are rarely observed. The current study presents a rare case of HSP with an intestinal tumour-like lesion in the caecum. The intestinal lesion caused fresh melaena, and was completely resolved with the administration of factor XIII as described in previously reported cases. It is important to immediately undergo proper treatment for improving tumour-like lesions which may cause severe complications, such as excessive haemorrhage and stricture.

BACKGROUND

Henoch-Schönlein purpura (HSP) is a type of systemic vasculitis of the small vessels, whose aetiology is still unclear but is associated with infections, medications, vaccination, tumours, α -1-antitrypsin deficiency and familial Mediterranean fever.¹ The characteristic symptoms and signs of HSP include a palpable purpuric rash, abdominal pain, arthralgia and nephritis.² GI involvement is an important clue for the diagnosis of typical and atypical HSP in which gastrointestinal (GI) lesions occur before or without the skin rash.³⁻⁴ Common GI lesions have been described as diffuse mucosal redness, small ring-like petechiae and haemorrhagic erosions, which are predominantly located in the small intestine.⁵⁻⁶ However, few atypical lesions resembling a solid submucosal tumour have so far been described in patients presenting with HSP in the intestine, and it is also thought to be one of the causes of intractable

bleeding and the later occurrence of stricture in the GI tract.⁷⁻⁸

For the treatment of HSP, paracetamol, non-steroidal anti-inflammatory drugs and steroids are frequently utilised,⁹ and subsequently immunomodulators are indicated if steroids alone is refractory.¹⁰ In addition, factor XIII administration has been proposed as an adjunctive therapy when other modalities are found to be ineffective, since factor XIII levels are found to be low in HSP patients because of the local consumption of clotting factors.¹¹⁻¹² This report presents a case of HSP developing a large submucosal tumour-like lesion in the colon, which was cured shortly after the administration of factor XIII.

CASE PRESENTATION

A 22-year-old male visited our hospital due to a 2-week history of upper abdominal pain in January 2010. He also

Figure 1 A pruritic rash of both the knee and feet. A pruritic rash appeared at the thighs, knee (A) and feet (B).

developed a pruritic rash which progressed proximally from both thighs to the feet since approximately 10 days before presentation (figure 1A,B). A blood examination revealed a high number of white blood cells (16040/ μ l; 70.05% of neutrophil, 18.1% of lymphocyte, 9.1% of monocyte, 0.3% of basophil and 1.0% of eosinophil), a high level of C reactive protein (6.36 mg/dl) and a low level of factor XIII (41%). The peripheral haemoglobin levels (14.0 g/dl), % prothrombin time (78%), activated partial thromboplastin time (34.9 s) and the number of peripheral platelets were all within the normal ranges (table 1).

Gastroduodenoscopy was performed after obtaining the patient's written informed consent to determine the cause of the upper abdominal pain. The examination detected multiple erosions and irregular-shaped ulcerations, which corresponded to the typical lesions of HSP, in the bulbous to the third portion of the duodenum (figure 2A,B). Conversely, colonoscopy detected a 2 cm-sized tumour-like lesion in the caecum (figure 2C). The lesion revealed a rounded elevation with a smooth edge and deep irregular ulceration in the centre, altering the typical intestinal findings of HSP. Although histological specimens obtained from the duodenum and the tumour-like lesion of the caecum revealed the infiltration of

neutrophils, eosinophils and lymphocytes without vasculitis, he was diagnosed to have HSP because of the palpable purpuric rash and the abdominal symptoms with typical GI involvement.¹³ However, it remains difficult to differentially diagnose the tumour-like lesion to be a benign lesion which developed due to the involvement of HSP. To eliminate the modulation of the inflammatory change due to HSP and determine whether the tumour-like lesion is a neoplasm or not, the treatment of HSP was thus started.

DIFFERENTIAL DIAGNOSIS

The disorders that would be included in the differential diagnosis based on the atypical tumour-like lesion in this case would be: colonic neoplasms including colon cancer, malignant lymphoma and carcinoid and GI stromal tumours.

OUTCOME AND FOLLOW-UP

Steroids (40 mg) were administered for 5 days to relieve the skin and abdominal symptoms; however, these symptoms thereafter again progressed and fresh melaena appeared. We therefore considered standard steroid therapy not to be effective in this case, and factor XIII was administered for 3 days. These symptoms and the GI lesions including the ulcerations and the tumour-like lesion almost completely vanished 10 days after the treatment (figure 2D–F). The serum level of factor XIII was returned to a normal range and no relapse of the abdominal symptoms was observed during the follow-up period (6 months).

DISCUSSION

This report presents a rare case of HSP which developed a submucosal tumour-like lesion in the caecum which caused the occurrence of fresh melaena, was resistant to steroid treatment and therefore was cured with the administration of factor XIII. This suggests that careful attention needs to be paid to atypical lesions such as tumour-like elevations in patients with HSP, which may cause complications such as GI haemorrhaging. Three cases including the present case, that reported HSP with tumour-like lesions in the small and large intestine are summarised in table 2.^{7 8}

The age of the patients with tumour-like lesions was from 20 to 59, and two patients were male and the other was female. The locations of the tumour-like lesions were the descending colon, second portion of duodenum and caecum. Two cases showed haemorrhage and one case developed stricture of the descending colon, thus indicating that the tumour-like lesions in the small and large intestine of the patients with HSP may cause severe complication. The effective treatments for the tumour-like lesions were the administration of factor XIII in two cases. Factor XIII is thought to be consumed for repairing the injury of the GI tissues and resolved by protease released from neutrophils in HSP.¹⁴ This suggests that the treatment with factor XIII is a feasible strategy to treat such tumour-like lesions in HSP patients when the patient

Table 1 Haematological examination

Peripheral blood		
White blood cell (/ μ l)	16040	(3500–8500)
Neutrophil (%)	70.1	(40.0–70.0)
Lymphocyte (%)	18.1	(20.0–50.0)
Monocyte (%)	9.1	(2.0–9.0)
Basophil (%)	0.3	(0–2.0)
Eosinocyte (%)	1	(1.0–6.0)
Red blood cell ($\times 10^4$ / μ l)	467	(430–570)
Haemoglobin (g/dl)	14	(13.5–17.0)
Haematocrit (%)	40.6	(40.0–50.0)
Platelet ($\times 10^4$ / μ l)	52.9	(150–350)
Coagulation		
Prothrombin time (%)	78	(70–140)
Activated partial thrombin time (%)	34.9	(24.0–40.0)
Fibrinogen (mg/dl)	478	(160–350)
D-dimer (μ g/ml)	17.87	(0–0.5)
Fibrin degradation product (μ g/ml)	32.1	(0–9.9)
Factor XIII (%)	41	(70–130)
Biochemistry		
Total protein (g/dl)	6.3	(6.0–8.0)
Albumin (g/dl)	3.2	(3.8–5.3)
Total bilirubin (mg/dl)	0.7	(0.2–1.0)
Aspartate transaminase (IU/l)	19	(6–40)
Alanine transaminase (IU/l)	25	(6–37)
Lactate dehydrogenase (IU/l)	186	(105–210)
Alkaline phosphatase (IU/l)	195	(96–284)
γ glutamyl transpeptidase (IU/l)	36	(4–67)
Creatine kinase (IU/l)	46	(24–195)
Blood urea nitrogen (mg/dl)	7	(6–20)
Creatinine (mg/dl)	0.52	(0.4–1.3)
Sodium (mEq/l)	136	(135–150)
Potassium (mEq/l)	3.9	(3.5–5.0)
Chlorine (mEq/l)	97	(96–110)
Serology		
C reactive protein (mg/dl)	6.36	(0–0.30)
Antinuclear antibody	negative

Figure 2 Endoscopic findings in the small and large intestine. Endoscopic examination revealed multiple erosions and irregular-shaped ulceration in the bulbus (A) and third portion (B) of the duodenum and a tumour-like lesion in the caecum (C). The multiple ulcerations in the bulbus (D) and third portion (E) of the duodenum as well as the tumour-like lesion in the caecum (F) were completely resolved after the administration of factor XIII, thus suggesting the efficacy of factor XIII treatment for the intestinal lesions of HSP.

Table 2 Reported cases of HSP with tumorous lesions in the small and large intestine

Author	Age	Gender	Location	Complications	Effective treatment	Outcome	Reference number
Hosono <i>et al</i> (2008)	24	M	Descending colon	Stricture	Administration of factor XIII	Recovered	7
Kusagawa <i>et al</i> (2010)	59	F	Second portion of duodenum	Haemorrhage	Administration of steroid	Disappeared	8
Our case	22	M	Caecum	Haemorrhage	Administration of factor XIII	Disappeared	

presents a low serum level of factor XIII. The appropriate and immediate therapy of HSP is for preventing severe complications including haemorrhage and stricture, and eliminating such lesions. In addition, it was suggested that these lesions are related to the pathogenesis of HSP because such lesions in the intestine of all three cases were relieved after being treated for HSP. A histological specimen obtained from the tumour-like lesion showed no obvious vasculitis in the mucosal layer. While vasculitis was generally detected in the mucosal layer, several cases with inflammation and haemorrhagic necrosis in either the submucosal layer or deeper layer of the intestinal wall, in addition to the development of perforations, have been reported among the patients presenting HSP.¹⁵ These findings suggest that such tumour-like lesions are therefore considered to be formed by inflammation or vasculitis occurring in either the submucosa or muscularis propria, and the involvement may therefore explain the characteristic features observed for this tumour-like lesion in HSP.

In summary, a rare case of HSP with atypical tumour-like lesions in the caecum was herein described. The lesion caused haemorrhaging and then disappeared after the administration of factor XIII. It is important to immediately administer the appropriate treatment for HSP to resolve such tumour-like lesions as well as other symptoms associated with HSP.

Learning points

- ▶ The current study presents a rare case of HSP with an intestinal tumour-like lesion in the caecum. Only three such cases, including our present case, have been reported.
- ▶ Such tumour-like lesions cause severe haemorrhage and stricture, which lead to deterioration of abdominal symptoms.
- ▶ The tumour-like lesion appeared to be formed by the inflammation and haemorrhagic necrosis in either the submucosal layer or a deeper layer, because no obvious vasculitis or other severe changes were observed in the mucosal layer.
- ▶ Diagnostic treatment with the administration of steroids and factor XIII might be useful to confirm the diagnosis of HSP.
- ▶ The treatment with factor XIII is a feasible strategy to cure such tumour-like lesions in HSP patients when the patient presents with a low serum level of factor XIII. It is important to immediately begin treatment to improve these tumour-like lesions.

Competing interests None.

Patient consent Obtained.

REFERENCES

1. **Chen KR**, Carlson JA. Clinical approach to cutaneous vasculitis. *Am J Clin Dermatol* 2008;**9**:71–92.
2. **Saulsbury FT**. Henoch-Schönlein purpura. *Curr Opin Rheumatol* 2001;**13**:35–40.
3. **Trujillo H**, Gunasekaran TS, Eisenberg GM, *et al*. Henoch-Schönlein purpura: a diagnosis not to be forgotten. *J Fam Pract* 1996;**43**:495–8.
4. **Mrusek S**, Krüger M, Greiner P, *et al*. Henoch-Schönlein purpura. *Lancet* 2004;**363**:1116.
5. **Tomomasa T**, Hsu JY, Itoh K, *et al*. Endoscopic findings in pediatric patients with Henoch-Schönlein purpura and gastrointestinal symptoms. *J Pediatr Gastroenterol Nutr* 1987;**6**:725–9.
6. **Banerjee B**, Rashid S, Singh E, *et al*. Endoscopic findings in Henoch-Schönlein purpura. *Gastrointest Endosc* 1991;**37**:569–71.
7. **Hosono K**, Endo H, Inamori M, *et al*. Severe large-intestine involvement in adult-onset Henoch-Schönlein purpura: successful treatment with factor XIII concentrate. *Digestion* 2008;**78**:9.
8. **Kusagawa S**, Sugimoto K, Nojiri K, *et al*. Unique endoscopic images in a patient with Henoch-Schönlein purpura. *Intern Med* 2010;**49**:509.
9. **Roberts PF**, Waller TA, Brinker TM, *et al*. Henoch-Schönlein purpura: a review article. *South Med J* 2007;**100**:821–4.
10. **Weiss PF**, Feinstein JA, Luan X, *et al*. Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review. *Pediatrics* 2007;**120**:1079–87.
11. **Fukui H**, Kamitsuji H, Nagao T, *et al*. Clinical evaluation of a pasteurized factor XIII concentrate administration in Henoch-Schönlein purpura. Japanese Pediatric Group. *Thromb Res* 1989;**56**:667–75.
12. **Kawasaki K**, Komura H, Nakahara Y, *et al*. Factor XIII in Henoch-Schönlein purpura with isolated gastrointestinal symptoms. *Pediatr Int* 2006;**48**:413–15.
13. **Ozen S**, Pistorio A, Iusan SM, *et al*. Paediatric Rheumatology International Trials Organisation (PRINTO). EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. *Ann Rheum Dis* 2010;**69**:798–806.
14. **Henriksson P**, Hedner U, Nilsson IM. Factor XIII (fibrin stabilising factor) in Henoch-Schönlein's purpura. *Acta Paediatr Scand* 1977;**66**:273–7.
15. **Basu R**. Perforation of the bowel in Henoch-Schönlein purpura. *Arch Dis Child* 1959;**34**:342–3.

This pdf has been created automatically from the final edited text and images.

Copyright 2011 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit <http://group.bmj.com/group/rights-licensing/permissions>.
BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.

Please cite this article as follows (you will need to access the article online to obtain the date of publication).

Ando K, Fujiya M, Sugiyama R, Nata T, Nomura Y, Ueno N, Kashima S, Ishikawa C, Inaba Y, Ito T, Moriichi K, Okamoto K, Ikuta K, Watari J, Mizukami Y, Kohgo Y. Atypical tumour-like involvement of the colon in Henoch-Schönlein purpura successfully treated with the administration of factor XIII. *BMJ Case Reports* 2011; 10.1136/bcr.08.2010.3251, date of publication

Become a Fellow of BMJ Case Reports today and you can:

- ▶ Submit as many cases as you like
- ▶ Enjoy fast sympathetic peer review and rapid publication of accepted articles
- ▶ Access all the published articles
- ▶ Re-use any of the published material for personal use and teaching without further permission

For information on Institutional Fellowships contact consortiasales@bmjgroup.com

Visit casereports.bmj.com for more articles like this and to become a Fellow